摘要 |
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for antitumour immunotherapy. For this purpose, dendritic cells (DC), obtained from a patient's skin, spleen, bone marrow, thymus, lymph nodes, umbilical blood or peripheral blood (autologous DC) are introduced to the patient, with DC being introduced to the patient step-by-step. At the first stage the introduction of mature allogenic DC, loaded with a tumourspecific antigen, maturation of which is realised ex vivo, is performed. At the second stage not less than 24 hours, but not more than 120 hours after the first stage the re-introduction of allogenc DC is realised simultaneously with the introduction of immature autologous DC in situ in a tumour, with the tumour being subjected to an ablation impact preliminarily or simultaneously with DC introduction.EFFECT: application of the claimed method makes it possible to achieve an increased immune response by the introduction of a two-component immune agent, which consists of a sensitising dose of allogenous mature cells and a therapeutic dose of immature DC, with 10% of the therapeutic DC dose being sufficient for sensitisation.2 cl, 3 ex |